Cancers, Vol. 15, Pages 4682: PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?

Cancers, Vol. 15, Pages 4682: PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated? Cancers doi: 10.3390/cancers15194682 Authors: Carolina Mathias Vanessa Nascimento Kozak Jessica Maria Magno Suelen Cristina Soares Baal Victor Henrique Apolonio dos Santos Enilze Maria de Souza Fonseca Ribeiro Daniela Fiori Gradia Mauro Antonio Alves Castro Jaqueline Carvalho de Oliveira As immune checkpoint inhibitors (ICI) emerge as a paradigm-shifting treatment option for patients with advanced or metastatic cancer, there is a growing demand for biomarkers that can distinguish which patients are likely to benefit. In the case of triple-negative breast cancer (TNBC), characterized by a lack of therapeutic targets, pembrolizumab approval for high-risk early-stage disease occurred regardless of PD-L1 status, which keeps the condition in a biomarker limbus. In this review, we highlight the participation of long non-coding RNAs (lncRNAs) in the regulation of the PD-1/PD-L1 pathway, as well as in the definition of prognostic immune-related signatures in many types of tumors, aiming to shed light on molecules that deserve further investigation for a potential role as biomarkers. We also conducted a bioinformatic analysis to investigate lncRNAs already investigated in PD-1/PDL-1 pathways in other cancer types, considering the TNBC molecular context. In this sense, from the generated data, we evidence here two lncRNAs, UCA1 an...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research